Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Luspatercept in Low or Intermediate-1 Risk MDS (Extension of A536-03)
DRKS00007625Phase 2Recruiting
- Sponsor
- Acceleron Pharma Inc.
- Start
- Feb 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in myelodysplastic syndrome (MDS) and anaemia, sponsored by Acceleron Pharma Inc. Primary endpoint: Long-term safety of luspatercept. Started Feb 2015; status: recruiting.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)anaemia
Beyond the preview
Go deeper on DRKS00007625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00007625.